Lexeo Therapeutics, Inc. (LXEO): Capital Expenditures
$397.0K
Year ended 2025-12-31
$331.0K
Trailing 12 months to 2026-06-30
-16.1%
3-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $397.0K | -17.5% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $481.0K | +318.3% | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | $115.0K | -82.9% | 2025-03-24, From 2023-01-01 |
| 2022-12-31 | $672.0K | n/a | 2024-03-11, From 2022-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | 2025-12-31 | $397.0K | -17.5% |
| Tectonic Therapeutic, Inc. (TECX) | 2025-12-31 | $208.0K | +33.3% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $155.0K | +10.7% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $2.60M | -26.3% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $0 | -100.0% |
| Alector, Inc. (ALEC) | 2025-12-31 | $41.0K | -96.7% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $886.0K | -81.1% |
| Kyverna Therapeutics, Inc. (KYTX) | 2025-12-31 | $5.0K | -99.8% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $3.83M | -22.8% |
Compare LXEO, TECX, IVVD, VYGR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗